GSK_ Annual_Report_2021-22

GlaxoSmithKline Pharmaceuticals Limited | Annual Report 2021-22 Notes to the Consolidated Financial Statements for the year ended March 31, 2022 224 ( ` in lakhs ) Outstanding as at March 31, 2021 Not due Less than 6 months 6 months - 1 year 1-2 years 2-3 years More than 3 years Total (i) Undisputed trade receivables - considered good 142,06.26 68,04.49 64.86 4,40.71 44.14 - 215,60.46 (ii) Undisputed trade receivables - which have significant increase in credit risk 5.01 61.26 29.77 1,23.21 97.92 13,54.05 16,71.22 (iii) Disputed trade receivables - which have significant increase in credit risk - - 2.16 33.75 53.37 2,46.57 3,35.85 Less : Allowance for doubtful receivables (20,07.07) Total 215,60.46 Note 12 : Cash and cash equivalents ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Balances with Banks: Current account 56,12.71 206,11.92 Term deposits with original maturity period of less than three months 230,06.00 199,07.00 286,18.71 405,18.92 Note 13 : Bank balances other than cash and cash equivalents ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Earmarked Balances: Unclaimed dividend accounts 18,28.05 19,86.36 Term deposits with original maturity period of more than three months but less than twelve months 2179,10.00 732,00.00 Margin money 94.02 91.12 2198,32.07 752,77.48 Note 14 : Current financial assets - Others ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 (Unsecured considered good) Receivable from group companies 63,89.36 17,89.12 Interest accrued on deposits with banks 7,63.71 7,50.83 Advances recoverable 31.65 31.65 71,84.72 25,71.60 Note 15 : Other current assets ( ` in lakhs ) As at March 31, 2022 As at March 31, 2021 Balances with Government Authorities 9,72.50 46,34.50 Advance to Creditors 18,35.40 9,82.18 Prepayments and Prepaid Expenses 13,92.58 14,64.90 Others 4,03.36 5,72.29 46,03.84 76,53.87